| Stuart N Rice, MD | |
|
33 Overlook Rd, Ste 311, Summit, NJ 07901-3570 | |
| (908) 598-1500 | |
| Not Available |
| Full Name | Stuart N Rice |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 44 Years |
| Location | 33 Overlook Rd, Summit, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366403610 | NPI | - | NPPES |
| 4517504 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 25MA05618400 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Morris Anesthesia Group Pa | 4284628645 | 47 |
| North American Partners In Anesthesia Of New Jersey Llc | 5890867410 | 226 |
News Archive
The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.
Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.
The new Tandem fund of $300 million announced last week presents a much-needed financing option for Canada's biotechnology industry. The Fund received investments from the Business Development Bank of Canada (BDC), and Export Development Canada (EDC), contributing $80 and $75 million respectively to the Fund.
› Verified 2 days ago
| Entity Name | Morris Anesthesia Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194728501 PECOS PAC ID: 4284628645 Enrollment ID: O20040409000402 |
News Archive
The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.
Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.
The new Tandem fund of $300 million announced last week presents a much-needed financing option for Canada's biotechnology industry. The Fund received investments from the Business Development Bank of Canada (BDC), and Export Development Canada (EDC), contributing $80 and $75 million respectively to the Fund.
› Verified 2 days ago
| Entity Name | North American Partners In Anesthesia Of New Jersey Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548433048 PECOS PAC ID: 5890867410 Enrollment ID: O20080626000318 |
News Archive
The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.
Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.
The new Tandem fund of $300 million announced last week presents a much-needed financing option for Canada's biotechnology industry. The Fund received investments from the Business Development Bank of Canada (BDC), and Export Development Canada (EDC), contributing $80 and $75 million respectively to the Fund.
› Verified 2 days ago
| Entity Name | Wound Healing Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932585445 PECOS PAC ID: 2668789116 Enrollment ID: O20150915003096 |
News Archive
The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.
Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.
The new Tandem fund of $300 million announced last week presents a much-needed financing option for Canada's biotechnology industry. The Fund received investments from the Business Development Bank of Canada (BDC), and Export Development Canada (EDC), contributing $80 and $75 million respectively to the Fund.
› Verified 2 days ago
| Entity Name | James Marc Schlesinger Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700265915 PECOS PAC ID: 7012218571 Enrollment ID: O20151229001144 |
News Archive
The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.
Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.
The new Tandem fund of $300 million announced last week presents a much-needed financing option for Canada's biotechnology industry. The Fund received investments from the Business Development Bank of Canada (BDC), and Export Development Canada (EDC), contributing $80 and $75 million respectively to the Fund.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stuart N Rice, MD Po Box 48078, Newark, NJ 07101-4878 Ph: () - | Stuart N Rice, MD 33 Overlook Rd, Ste 311, Summit, NJ 07901-3570 Ph: (908) 598-1500 |
News Archive
The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.
Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.
The new Tandem fund of $300 million announced last week presents a much-needed financing option for Canada's biotechnology industry. The Fund received investments from the Business Development Bank of Canada (BDC), and Export Development Canada (EDC), contributing $80 and $75 million respectively to the Fund.
› Verified 2 days ago
Chang Kweon, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 33 Overlook Rd, Ste 311, Summit, NJ 07901 Phone: 908-598-1500 | |
Jason Byers, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 33 Overlook Rd, Ste 311, Summit, NJ 07901 Phone: 908-598-1500 | |
Dr. Dmitry Rozin, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 99 Beauvoir Ave, Summit, NJ 07901 Phone: 908-522-2000 | |
Kathleen M Boreale, NP Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 11 Overlook Road, Suite B110, Summit, NJ 07901 Phone: 908-522-2709 | |
Ryan Edward Boyne, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 99 Beauvoir Ave, Summit, NJ 07901 Phone: 516-945-3000 | |
Carol E Zimmermann, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 33 Overlook Rd, Ste 311, Summit, NJ 07901 Phone: 908-598-1500 | |
Shekhar C. Karmaker, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 33 Overlook Rd, Suite 311, Summit, NJ 07901 Phone: 908-944-5204 |